Introduction
Medications play a significant role in managing health issues, especially in elderly individuals who often face multiple chronic conditions. While these drugs are meant to relieve symptoms and enhance quality of life, the combined impact, known as polypharmacy, can sometimes cause more harm than good. Juggling multiple chronic conditions can lead to safety issues, unwanted drug reactions, and decreased functional abilities. This paper explores the complexities of incorporating care to tackle polypharmacy challenges, the contributions of practice nurses in addressing these hurdles, strategies for minimizing polypharmacy and the ethical and legal aspects at play.
Polypharmacy Challenges
A key challenge in implementing care is the lack of awareness and understanding among healthcare providers and patients. Many view palliative care as end-of-life support without realizing its significance in managing conditions and reducing polypharmacy risks. Moreover, obstacles like access to palliative care services in rural areas and insufficient insurance coverage further hinder progress.
Advanced practice nurses (APNs) are essential in addressing these obstacles. Locally, APNs have the ability to enlighten patients and their families on the advantages of palliative care for chronic conditions and the dangers linked to taking multiple medications (McNeil et al., 2016). They can also push for the inclusion of palliative care in primary care facilities to ensure that all individuals who require it have access. On a broader scale, APNs can impact health policies by advocating for expanded insurance coverage for palliative care services and endorsing laws that back interdisciplinary palliative care groups.
Addressing Polypharmacy
To reduce polypharmacy, especially in palliative and hospice care, a comprehensive review of the patient’s medication regimen is essential. This involves evaluating each medication for its current relevance to the patient’s care goals, potential drug-drug interactions, and the risk of adverse effects (McNeil et al., 2016). The deprescribing process, which is the systematic reduction or stopping of drugs that may no longer be beneficial or might be causing harm, is a critical method of care in this context. This process requires careful assessment of the patient’s condition, close monitoring for withdrawal symptoms or disease exacerbation, and ongoing communication with the patient and their family.
In cases of chronic illness, reducing polypharmacy or deprescribing involves prioritizing medications that directly contribute to the patient’s quality of life and align with their care goals (Bukowy & Teso, n.d.). This often means focusing on symptom management, comfort, and palliative care over aggressive disease-modifying therapies. APNs must consider the patient’s values, preferences, and life expectancy when making these decisions.
Reducing polypharmacy raises several ethical and legal considerations. Ethically, the principle of non-maleficence, or “do no harm,” supports the reduction of unnecessary medications that might cause adverse effects. However, the principle of autonomy requires that patients are fully informed about their treatment options and involved in decision-making processes. Legally, APNs must document their rationale for deprescribing and ensure that their actions are consistent with professional guidelines and standards of care to avoid potential malpractice claims (Halli-Tierney et al., 2019).
Conclusion
In summary, polypharmacy presents a challenge for individuals with multiple chronic conditions, necessitating careful management and thoughtful deliberation. Through their roles in care, education, and advocacy, advanced practice nurses can promote the adoption of palliative care strategies to address polypharmacy concerns. By focusing on deprescribing practices and aligning medication use with patient-centered objectives, APNs can address safety issues associated with polypharmacy. However, they must navigate dilemmas and legal ramifications carefully to safeguard their patients’ well-being.
References
Bukowy, E. A. & Teso, K. (n.d.). Deprescribing at the end of life: When less is more.
Halli-Tierney, A. D., Scarbrough, C., & Carroll, D. (2019). Polypharmacy: Evaluating risks and deprescribing. American Family Physician, 100(1), 32-38.
McNeil, M. J., Kamal, A. H., Kutner, J. S., Ritchie, C. S., & Abernethy, A. P. (2016). The burden of polypharmacy in patients near the end of life. Journal of Pain and Symptom Management, 51(2), 178-183.